Takeda Pharmaceutical Company Limited (TAK)
After hours:
| Previous Close | 14.20 |
| Open | 14.20 |
| Bid | 0.00 x 3100 |
| Ask | 0.00 x 1400 |
| Day's Range | 14.14 - 14.26 |
| 52 Week Range | 13.05 - 17.31 |
| Volume | |
| Avg. Volume | 2,529,022 |
| Market Cap | 44.451B |
| Beta (5Y Monthly) | 0.80 |
| PE Ratio (TTM) | 30.17 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.80 (5.66%) |
| Ex-Dividend Date | Sept 29, 2021 |
| 1y Target Est | N/A |
- GlobeNewswire
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease (“CKD”), today announce
- Business Wire
Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance
OSAKA, Japan, July 28, 2022--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the first quarter of fiscal year 2022 (period ended June 30, 2022) and is on track to meet its full-year management guidance.
- Business Wire
Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
OSAKA, Japan & CAMBRIDGE, Mass., July 21, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase 3 clinical trial evaluating HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint. Topline data show that HYQVIA reduced relapse of neuromuscular disability and impairment when used as a
